论文部分内容阅读
为了解在临床常用量下口服胸腺肽胶囊及其半成品 ( 胸腺肽液体) 对人体的毒性反应和安全性大小, 对 S D 大鼠、 N I H 小白鼠分别灌胃给予胸腺肽胶囊剂混悬液、胸腺肽液体进行最大耐受量试验: 腹腔注射给予 N I H 小白鼠胸腺肽液体进行急性毒性试验。结果表明, S D 大鼠、 N I H 小白鼠分别灌胃给予相应药物, L D50 均大于6 g/kg ; N I H 小白鼠腹腔注射给药, L D50 = 184 g/kg , L D50 可信限= 178 ~190 g/kg , L D50 平均可信限率= 33 % 。说明, 口服胸腺肽胶囊及其半成品毒性小、应用安全。
To understand the toxicity and safety of oral administration of thymosin capsules and their semi-finished products (thymosin liquid) in clinical practice, SJ rats and NIH mice were orally administered with thymosin capsule suspension, thymosin Liquid maximum tolerance test: intraperitoneal injection of N I H mouse thymosin liquid for acute toxicity test. The results showed that, S D rats, N I H mice were given the corresponding drug by gavage, L D50 were greater than 6 g / kg; NIH mice by intraperitoneal injection, L D50 = 1 84 g / kg, L D50 credible limit = 178 ~ 190 g / kg, L D50 average credible limit rate = 33%. Description, oral thymosin capsules and semi-finished products of small toxicity, application safety.